SlideShare a Scribd company logo
1 of 26
Disclosure Information: clinical research grants from: BMS, Bayer  Jose López-Sendón Hospital Universitario La Paz. Madrid Antagonistas del receptor A1 de Adenosina Nuevo pardigma en el tratamiento de la insuficiencia cardiaca aguda
The old times. Heart failure as a congestive syndrome
Adams KF et al. Am Heart J. 2005; 149: 209 Cleland JGF et al. Eur Heart J. 2003; 24: 442 Fonarow GC et al. J Am Coll Cardiol. 2005; 45: 345A Hospitalizations for HF: Patient Characteristics ADHERE EURO HF OPTIMIZE-HF (%) (107,920 pts.) (11,327 pts.) (48,612 pts.) Any dyspnea 89 70 90? Dyspnea at rest 34 40 45 Fatigue 32 35 23 Rales 68 N/A 65 Peripheral edema 66 23 65
60-Day All-cause Mortality 0% 10% 20% N =  204  115  (64%)  (36%)  ACTIVE in CHF   Adapted from Gheorghiade M et al. JAMA. 2004;291:1963 Congestion after Initial In-Hospital Therapy is Associated with Higher 60-day Mortality Severe  Congestion* 7.8 3.5 No Severe  Congestion*
Bayliss et al. Br Heart J. 1987; 57: 17 Neurohormonal effect of Diuretics in Heart Failure Basal (n=12) Plasma Renin Activity (ng/mL/h) 50 10 2.5 0.5 P  =.0002 After Diur étic (n=11) Plasma Aldosterone (pmol/L) % 1000 600 200 100 P  =.0007 Basal (n=12) After Diuretic (n=11)
Resistencia  a diuréticos Incremento de la Mortalidad y  Morbilidad  Tratamiento diur ético Insuficiencia renal Disminuci ón de la función renal Desarrollo de Resistencia a  Diur éticos Disminuci ón Flujo sanguíneo Activaci ón Neurohormonal
Incidencia de Insuf. Renal en Insf. Cardiaca 13 10 4 12 9 6 41 21 16 27 1.8 30 0 5 10 15 20 25 30 35 ADHERE OSCUR internista OSCUR cardiologo HGM cardiologo ICCAR ambulatorio EHFS-1 Rusia EHFS 1 Holanda EHFS-1 España EHFS-1 Media EVEREST VALIANT MADIT 2 Registros Ensayos cl ínicos % EHFS-2  ICC EHFS-2  ICA 21 11 0 5 10 15 20 25 30 35
Incidencia de IR en IC 43,3% 41,8% Pacientes (nº) FEVI  ≥  50%  FEVI < 50% Insuficiencia Renal: TFG < 60 ml/min/1.73m2 Grigorian L, et al . REC 2006:59:99
Insuficiencia cardiaca aguda Factores relacionados con  Mortalidad intrahospitalaria   EHFS-II: n=3432 L ó pez-Send ón et al  ECC 2007
Función Renal y Pron óstico FEVI  ≥  50%  FEVI < 50% Grigorian L, et al . REC 2006:59:99 TFG < 30 TFG < 30 TFG 30-60 TFG 30-60 TFG > 60 TFG > 60 RR  (ajustado) TFG<30/>60 : 2.86; p=0.021 RR  (ajustado) TFG<30/>60 : 3.79; p=0.011 RR  (ajustado) TFG 30-60/>60 : 1.44; p=NS RR  (ajustado) TFG 30-60/>60 : 1.02; p=NS
NA +  and H 2 O RETENTION SNS 1   Efferent art. constriction 2  Na +  reabs. in prox. tubule Angiotensin 1 Efferent art. constriction 2  Na +  reabs. in prox. tubule Aldosterone 3  Reabsorption H 2 O and Na+ 4   K +  Secretion Vasopressin 5  H 2 O   reabs. in collecting tubule 6  Na +  reabs. in ascending branch  of the loop of Henle Adenosin 1b  A fferent art. constriction 1  Na +  reabs. in prox. tubule Atrial Natriuretic P 7 Increase glomerular filtration 8  Na reabs. in collecting tubule Renal Prostaglandins  9  Afferent art. vasodilatation 10 Reduce Na +  reabsorption  in asc. branch of loop of Henle 11 Inhibit Na +  reabsorption in  collecting tubule 12 1 2 4 5 6 7 8 9 10 3 1b
New Diuretics ? •   BNP •   Endotelin antagonists  •   Adenosin receptor inh. •   Vasopresin antagonists •   Aldosterone inhibitors
Adenosin A1 Receptors Reabsorción de Na+ Vasoconstricción Adenosin A1 receptors: Afferent arteriolar vasodilatation   Inhibit Na +  reabsorption  in the proximal tubule and enhance diuresis Block adenosine-mediated tubo-glomerular feedback .
Adenosine A1 receptor antagonists ,[object Object],[object Object]
A1 receptor Blockers Rolofillyne (KW-3902)  BG9928  BG9719 (CVT-124) SLV320
BG9719, an A1R antagonist, protects against the decline in renal function observed with diuretic therapy  n = 63, NYHA class II-IV, EF    40% and edema despite furosemide (80 mg/d) IV BG9928 (3, 15, 75 y 225 mg) vs placebo for 10 days BG9719 increased urine output, sodium excretion and GFR Furosemide increased urine output at the expense of decreased GFR  BG9719 plus furosemide increased diuresis without deterioration in GFR Decrease in body weight of 0.6 kg (0.3 kg with placebo) Gottlieb et al. JACC 2000;35:56-59
CKI-201 -  ADHF patients with renal impairment  Cumulative Urine Volume and daily dose of i.v. furosemide Day 1 Day 2 Day 3 0 40 80 120 160 * Daily dose of i.v. Furosemide (mg) * P  < 0.05 vs. placebo).  Givertz et al. JACC 2007; 50:1551-1560  By day 4 or day of discharge if earlier, i.v. furosemide administration tended to be lower in the KW-3902 group Placebo 2.5 mg 30 mg 60 mg 15 mg
CKI-202 –   ADHF patients refractory to diuretics   Hourly Urine Volume and Creatinine Clearance (34 ml/min) * P  < 0.05 vs. placebo Givertz et al. JACC 2007; 50:1551-1560  Enhances the response to loop diuretics and may have a renal protective effect I ncrease Na +  excretion that with &quot;little kaliuresis“ Decreases BW, improves dyspnea and edemas No change in morbidity and mortality for worsening of HF
Pilot study 301 patients Barry M. Massie For the  PROTECT  Investigators and Coordinators
PROTECT Studies:  Primary  Endpoint ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Pilot Phase – Methods (1) ,[object Object],[object Object],[object Object],[object Object],[object Object]
PROTECT Primary Endpoint 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Placebo  (n=78) 10 mg  (n=74) 20 mg  (n=75) 30 mg  (n=74) Treatment group % subjects Failure Unchanged Success
PROTECT 60 Day Outcomes:  Death and Rehospitalization 1 30 mg vs placebo: HR 0.55 (95% CI = 0.28,1.04)   Placebo Rolofylline (n=78)  10 mg (n=74)  20 mg (n=75)  30 mg (n=74)  Death or cardiovascular or renal rehospitalization 1 33% 32% 24% 19% Death 10% 12% 8% 5% Rehospitalization for cardiovascular or renal causes 30% 22% 17% 16%
Conclusions ,[object Object],[object Object],[object Object]
 
Conclusions •   Adenosin harmful in HF •   A1 blockade promissing in Acute HF •   Protect trial a deception •  Drug w real benefit in acute heart failure still missing (and much needed)

More Related Content

What's hot

Valvulopatias Medicina Interna Enfoque Practico
Valvulopatias Medicina Interna Enfoque PracticoValvulopatias Medicina Interna Enfoque Practico
Valvulopatias Medicina Interna Enfoque Practicojefersonmancilla
 
Dr jeevraj Low Cardiac Output In cardiac surgery
Dr jeevraj Low Cardiac Output In cardiac surgeryDr jeevraj Low Cardiac Output In cardiac surgery
Dr jeevraj Low Cardiac Output In cardiac surgeryjeevraj24
 
Reversal of antithrombotic agent
Reversal of antithrombotic agentReversal of antithrombotic agent
Reversal of antithrombotic agentAnkit Gajjar
 
Adressing Radial Artery Spasm
Adressing Radial Artery SpasmAdressing Radial Artery Spasm
Adressing Radial Artery SpasmDya Andryan
 
Pathophysiology of ccp and cardiac tamponade
Pathophysiology of ccp and cardiac tamponadePathophysiology of ccp and cardiac tamponade
Pathophysiology of ccp and cardiac tamponadeVallabhaneni Bhupal
 
Wide complex tacycardia
Wide complex tacycardiaWide complex tacycardia
Wide complex tacycardiaKush Bhagat
 
Hyponatremia (Into Practice) - Dr. Gawad
Hyponatremia  (Into Practice) - Dr. GawadHyponatremia  (Into Practice) - Dr. Gawad
Hyponatremia (Into Practice) - Dr. GawadNephroTube - Dr.Gawad
 
Electrocardiograma EKG
Electrocardiograma EKGElectrocardiograma EKG
Electrocardiograma EKGKenny Lopez
 
Insuficiencia cardíaca crónica resistente a tratamiento diurético.
Insuficiencia cardíaca  crónica resistente a tratamiento diurético.Insuficiencia cardíaca  crónica resistente a tratamiento diurético.
Insuficiencia cardíaca crónica resistente a tratamiento diurético.docenciaaltopalancia
 
Major Acute Hemodialysis Complications - Hoping to Prevent - Dr. Gawad
Major Acute Hemodialysis Complications - Hoping to Prevent - Dr. GawadMajor Acute Hemodialysis Complications - Hoping to Prevent - Dr. Gawad
Major Acute Hemodialysis Complications - Hoping to Prevent - Dr. GawadNephroTube - Dr.Gawad
 
Anti Platelet Agents
Anti Platelet AgentsAnti Platelet Agents
Anti Platelet AgentsRahul Kumar
 
His resynchronization versus biventricular pacing
His resynchronization versus biventricular pacingHis resynchronization versus biventricular pacing
His resynchronization versus biventricular pacingAlireza Ghorbani Sharif
 
Refractory Edema with CHF - Stepwise Approaches - Nephrology Perspectives - D...
Refractory Edema with CHF - Stepwise Approaches - Nephrology Perspectives - D...Refractory Edema with CHF - Stepwise Approaches - Nephrology Perspectives - D...
Refractory Edema with CHF - Stepwise Approaches - Nephrology Perspectives - D...NephroTube - Dr.Gawad
 

What's hot (20)

Valvulopatias Medicina Interna Enfoque Practico
Valvulopatias Medicina Interna Enfoque PracticoValvulopatias Medicina Interna Enfoque Practico
Valvulopatias Medicina Interna Enfoque Practico
 
Dr jeevraj Low Cardiac Output In cardiac surgery
Dr jeevraj Low Cardiac Output In cardiac surgeryDr jeevraj Low Cardiac Output In cardiac surgery
Dr jeevraj Low Cardiac Output In cardiac surgery
 
Estenosis pulmonar
Estenosis pulmonarEstenosis pulmonar
Estenosis pulmonar
 
Hipertension intracraneal Zarranz
Hipertension intracraneal ZarranzHipertension intracraneal Zarranz
Hipertension intracraneal Zarranz
 
Reversal of antithrombotic agent
Reversal of antithrombotic agentReversal of antithrombotic agent
Reversal of antithrombotic agent
 
Adressing Radial Artery Spasm
Adressing Radial Artery SpasmAdressing Radial Artery Spasm
Adressing Radial Artery Spasm
 
Pathophysiology of ccp and cardiac tamponade
Pathophysiology of ccp and cardiac tamponadePathophysiology of ccp and cardiac tamponade
Pathophysiology of ccp and cardiac tamponade
 
Wide complex tacycardia
Wide complex tacycardiaWide complex tacycardia
Wide complex tacycardia
 
Hyponatremia (Into Practice) - Dr. Gawad
Hyponatremia  (Into Practice) - Dr. GawadHyponatremia  (Into Practice) - Dr. Gawad
Hyponatremia (Into Practice) - Dr. Gawad
 
Electrocardiograma EKG
Electrocardiograma EKGElectrocardiograma EKG
Electrocardiograma EKG
 
AVNRT
AVNRTAVNRT
AVNRT
 
Wide complex tachycardia
Wide complex tachycardiaWide complex tachycardia
Wide complex tachycardia
 
Insuficiencia cardíaca crónica resistente a tratamiento diurético.
Insuficiencia cardíaca  crónica resistente a tratamiento diurético.Insuficiencia cardíaca  crónica resistente a tratamiento diurético.
Insuficiencia cardíaca crónica resistente a tratamiento diurético.
 
Major Acute Hemodialysis Complications - Hoping to Prevent - Dr. Gawad
Major Acute Hemodialysis Complications - Hoping to Prevent - Dr. GawadMajor Acute Hemodialysis Complications - Hoping to Prevent - Dr. Gawad
Major Acute Hemodialysis Complications - Hoping to Prevent - Dr. Gawad
 
Anti Platelet Agents
Anti Platelet AgentsAnti Platelet Agents
Anti Platelet Agents
 
His resynchronization versus biventricular pacing
His resynchronization versus biventricular pacingHis resynchronization versus biventricular pacing
His resynchronization versus biventricular pacing
 
Plato trial
Plato trialPlato trial
Plato trial
 
Refractory Edema with CHF - Stepwise Approaches - Nephrology Perspectives - D...
Refractory Edema with CHF - Stepwise Approaches - Nephrology Perspectives - D...Refractory Edema with CHF - Stepwise Approaches - Nephrology Perspectives - D...
Refractory Edema with CHF - Stepwise Approaches - Nephrology Perspectives - D...
 
Wolff - Parkinson - White Syndrome
Wolff - Parkinson - White SyndromeWolff - Parkinson - White Syndrome
Wolff - Parkinson - White Syndrome
 
Teoría Desfibrilación
Teoría DesfibrilaciónTeoría Desfibrilación
Teoría Desfibrilación
 

Viewers also liked

Viewers also liked (8)

Como mejorar el reconocimiento de las inmunodeficiencias primarias
Como mejorar el reconocimiento de las inmunodeficiencias primariasComo mejorar el reconocimiento de las inmunodeficiencias primarias
Como mejorar el reconocimiento de las inmunodeficiencias primarias
 
Trifosfato de adenosina
Trifosfato de adenosinaTrifosfato de adenosina
Trifosfato de adenosina
 
Idp2
Idp2Idp2
Idp2
 
Adenosina
AdenosinaAdenosina
Adenosina
 
Fármacos antiarrítmicos
Fármacos antiarrítmicosFármacos antiarrítmicos
Fármacos antiarrítmicos
 
Pharmacology kinetic and clearance
Pharmacology   kinetic and clearancePharmacology   kinetic and clearance
Pharmacology kinetic and clearance
 
Vademecum
VademecumVademecum
Vademecum
 
Adenosin Deaminasa (ADA)
Adenosin Deaminasa (ADA)Adenosin Deaminasa (ADA)
Adenosin Deaminasa (ADA)
 

Similar to Antagonistas del receptor de la Adenosina A1: nuevo paradigma en el tratamiento de la IC Aguda. Dr. José Luis López Sendón

Hypertension management- Angina IHD
Hypertension management- Angina IHDHypertension management- Angina IHD
Hypertension management- Angina IHDcardiositeindia
 
02 Sperati Prevention And Management Of Acute Renal Failure
02 Sperati   Prevention And Management Of Acute Renal Failure02 Sperati   Prevention And Management Of Acute Renal Failure
02 Sperati Prevention And Management Of Acute Renal FailureDang Thanh Tuan
 
02 Sperati Prevention And Management Of Acute Renal Failure
02 Sperati   Prevention And Management Of Acute Renal Failure02 Sperati   Prevention And Management Of Acute Renal Failure
02 Sperati Prevention And Management Of Acute Renal Failureguest2379201
 
Ufpresenterslides
UfpresenterslidesUfpresenterslides
Ufpresenterslideshospital
 
Thuốc điều trị tăng huyết áp trên bệnh thận đái tháo đường - BS Phạm Văn Bù...
Thuốc điều trị tăng huyết áp trên bệnh thận đái tháo đường - BS Phạm Văn Bù...Thuốc điều trị tăng huyết áp trên bệnh thận đái tháo đường - BS Phạm Văn Bù...
Thuốc điều trị tăng huyết áp trên bệnh thận đái tháo đường - BS Phạm Văn Bù...cacao83
 
Acute Heart Failure – The road to where
Acute Heart Failure – The road to whereAcute Heart Failure – The road to where
Acute Heart Failure – The road to wheredrucsamal
 
Update 2015- What's New From Cardiology Main Congresses JNUC4 2015 final
Update 2015- What's New From Cardiology Main Congresses JNUC4 2015 finalUpdate 2015- What's New From Cardiology Main Congresses JNUC4 2015 final
Update 2015- What's New From Cardiology Main Congresses JNUC4 2015 finalNicolas Peschanski, MD, PhD
 
Does it matter how congestion is relieved
Does it matter how congestion is relievedDoes it matter how congestion is relieved
Does it matter how congestion is relieveddrucsamal
 
Acute Kidney Dysfunction
Acute Kidney DysfunctionAcute Kidney Dysfunction
Acute Kidney DysfunctionAndrew Ferguson
 
Trv027 a biased ligand approach to improve outcomes.
Trv027 a biased ligand approach to improve outcomes.Trv027 a biased ligand approach to improve outcomes.
Trv027 a biased ligand approach to improve outcomes.Mukesh Mishra
 
Trv027 a biased ligand approach to improve outcomes.
Trv027 a biased ligand approach to improve outcomes.Trv027 a biased ligand approach to improve outcomes.
Trv027 a biased ligand approach to improve outcomes.drucsamal
 
25 chen acute renal failure
25 chen   acute renal failure25 chen   acute renal failure
25 chen acute renal failureDang Thanh Tuan
 
AKI IN CIRRHOSIS 1.pptx
AKI IN CIRRHOSIS 1.pptxAKI IN CIRRHOSIS 1.pptx
AKI IN CIRRHOSIS 1.pptxDrHarsh Saxena
 
Transition study and Pioneer HF study
Transition study and Pioneer HF studyTransition study and Pioneer HF study
Transition study and Pioneer HF studyEdgardo Kaplinsky
 

Similar to Antagonistas del receptor de la Adenosina A1: nuevo paradigma en el tratamiento de la IC Aguda. Dr. José Luis López Sendón (20)

Hypertension management- Angina IHD
Hypertension management- Angina IHDHypertension management- Angina IHD
Hypertension management- Angina IHD
 
02 Sperati Prevention And Management Of Acute Renal Failure
02 Sperati   Prevention And Management Of Acute Renal Failure02 Sperati   Prevention And Management Of Acute Renal Failure
02 Sperati Prevention And Management Of Acute Renal Failure
 
02 Sperati Prevention And Management Of Acute Renal Failure
02 Sperati   Prevention And Management Of Acute Renal Failure02 Sperati   Prevention And Management Of Acute Renal Failure
02 Sperati Prevention And Management Of Acute Renal Failure
 
Ufpresenterslides
UfpresenterslidesUfpresenterslides
Ufpresenterslides
 
Thuốc điều trị tăng huyết áp trên bệnh thận đái tháo đường - BS Phạm Văn Bù...
Thuốc điều trị tăng huyết áp trên bệnh thận đái tháo đường - BS Phạm Văn Bù...Thuốc điều trị tăng huyết áp trên bệnh thận đái tháo đường - BS Phạm Văn Bù...
Thuốc điều trị tăng huyết áp trên bệnh thận đái tháo đường - BS Phạm Văn Bù...
 
Lo mejor sobre Insuficiencia Cardiaca
Lo mejor sobre Insuficiencia CardiacaLo mejor sobre Insuficiencia Cardiaca
Lo mejor sobre Insuficiencia Cardiaca
 
Acute Heart Failure – The road to where
Acute Heart Failure – The road to whereAcute Heart Failure – The road to where
Acute Heart Failure – The road to where
 
Update 2015- What's New From Cardiology Main Congresses JNUC4 2015 final
Update 2015- What's New From Cardiology Main Congresses JNUC4 2015 finalUpdate 2015- What's New From Cardiology Main Congresses JNUC4 2015 final
Update 2015- What's New From Cardiology Main Congresses JNUC4 2015 final
 
Denervacion Renal otras indicaciones
Denervacion Renal otras indicacionesDenervacion Renal otras indicaciones
Denervacion Renal otras indicaciones
 
Does it matter how congestion is relieved
Does it matter how congestion is relievedDoes it matter how congestion is relieved
Does it matter how congestion is relieved
 
Acute Kidney Dysfunction
Acute Kidney DysfunctionAcute Kidney Dysfunction
Acute Kidney Dysfunction
 
Trv027 a biased ligand approach to improve outcomes.
Trv027 a biased ligand approach to improve outcomes.Trv027 a biased ligand approach to improve outcomes.
Trv027 a biased ligand approach to improve outcomes.
 
Trv027 a biased ligand approach to improve outcomes.
Trv027 a biased ligand approach to improve outcomes.Trv027 a biased ligand approach to improve outcomes.
Trv027 a biased ligand approach to improve outcomes.
 
Top 3 Hits en Insuficiencia cardiaca en 2014
Top 3 Hits en Insuficiencia cardiaca en 2014Top 3 Hits en Insuficiencia cardiaca en 2014
Top 3 Hits en Insuficiencia cardiaca en 2014
 
25 chen acute renal failure
25 chen   acute renal failure25 chen   acute renal failure
25 chen acute renal failure
 
AKI IN CIRRHOSIS 1.pptx
AKI IN CIRRHOSIS 1.pptxAKI IN CIRRHOSIS 1.pptx
AKI IN CIRRHOSIS 1.pptx
 
Transition study and Pioneer HF study
Transition study and Pioneer HF studyTransition study and Pioneer HF study
Transition study and Pioneer HF study
 
New horizons in ckd management
New horizons in ckd managementNew horizons in ckd management
New horizons in ckd management
 
Serelaxin.
Serelaxin.Serelaxin.
Serelaxin.
 
Serelaxin.
Serelaxin.Serelaxin.
Serelaxin.
 

More from guest6ee1ff

Registro Macional de Trasplante Cardiaco 2008. Dr. Luis Almenar Bonet
Registro Macional de Trasplante Cardiaco 2008. Dr. Luis Almenar BonetRegistro Macional de Trasplante Cardiaco 2008. Dr. Luis Almenar Bonet
Registro Macional de Trasplante Cardiaco 2008. Dr. Luis Almenar Bonetguest6ee1ff
 
IC descompensada y fracción de eyección ventricular izquierda normal. Dr. Ama...
IC descompensada y fracción de eyección ventricular izquierda normal. Dr. Ama...IC descompensada y fracción de eyección ventricular izquierda normal. Dr. Ama...
IC descompensada y fracción de eyección ventricular izquierda normal. Dr. Ama...guest6ee1ff
 
IC aguda e hipotensión. Dr. Luís Martínez Dolz
IC aguda e hipotensión. Dr. Luís Martínez DolzIC aguda e hipotensión. Dr. Luís Martínez Dolz
IC aguda e hipotensión. Dr. Luís Martínez Dolzguest6ee1ff
 
La resonancia nuclear magnética. Dr. Francisco Ridocci
La resonancia nuclear magnética. Dr. Francisco RidocciLa resonancia nuclear magnética. Dr. Francisco Ridocci
La resonancia nuclear magnética. Dr. Francisco Ridocciguest6ee1ff
 
El ecocardiograma. Dra. Violeta Sánchez
El ecocardiograma. Dra. Violeta SánchezEl ecocardiograma. Dra. Violeta Sánchez
El ecocardiograma. Dra. Violeta Sánchezguest6ee1ff
 
Manejo de la IC avanzada o refractaria. Dr. Nicolas Manito
Manejo de la IC avanzada o refractaria. Dr. Nicolas ManitoManejo de la IC avanzada o refractaria. Dr. Nicolas Manito
Manejo de la IC avanzada o refractaria. Dr. Nicolas Manitoguest6ee1ff
 
¿Qué aportan las nuevas guías de IC? Dr. Esteban López de Sa
¿Qué aportan las nuevas guías de IC? Dr. Esteban López de Sa¿Qué aportan las nuevas guías de IC? Dr. Esteban López de Sa
¿Qué aportan las nuevas guías de IC? Dr. Esteban López de Saguest6ee1ff
 
La responsabilidad del clínico. Dr Juan F. Delgado
La responsabilidad del clínico. Dr Juan F. DelgadoLa responsabilidad del clínico. Dr Juan F. Delgado
La responsabilidad del clínico. Dr Juan F. Delgadoguest6ee1ff
 
Programa ITERA - Dr.Josep Comín
Programa ITERA - Dr.Josep ComínPrograma ITERA - Dr.Josep Comín
Programa ITERA - Dr.Josep Comínguest6ee1ff
 
Realidad española de los programas de insuficiencia cardiaca. Dr. Josep Lupón
Realidad española de los programas de insuficiencia cardiaca. Dr. Josep LupónRealidad española de los programas de insuficiencia cardiaca. Dr. Josep Lupón
Realidad española de los programas de insuficiencia cardiaca. Dr. Josep Lupónguest6ee1ff
 

More from guest6ee1ff (10)

Registro Macional de Trasplante Cardiaco 2008. Dr. Luis Almenar Bonet
Registro Macional de Trasplante Cardiaco 2008. Dr. Luis Almenar BonetRegistro Macional de Trasplante Cardiaco 2008. Dr. Luis Almenar Bonet
Registro Macional de Trasplante Cardiaco 2008. Dr. Luis Almenar Bonet
 
IC descompensada y fracción de eyección ventricular izquierda normal. Dr. Ama...
IC descompensada y fracción de eyección ventricular izquierda normal. Dr. Ama...IC descompensada y fracción de eyección ventricular izquierda normal. Dr. Ama...
IC descompensada y fracción de eyección ventricular izquierda normal. Dr. Ama...
 
IC aguda e hipotensión. Dr. Luís Martínez Dolz
IC aguda e hipotensión. Dr. Luís Martínez DolzIC aguda e hipotensión. Dr. Luís Martínez Dolz
IC aguda e hipotensión. Dr. Luís Martínez Dolz
 
La resonancia nuclear magnética. Dr. Francisco Ridocci
La resonancia nuclear magnética. Dr. Francisco RidocciLa resonancia nuclear magnética. Dr. Francisco Ridocci
La resonancia nuclear magnética. Dr. Francisco Ridocci
 
El ecocardiograma. Dra. Violeta Sánchez
El ecocardiograma. Dra. Violeta SánchezEl ecocardiograma. Dra. Violeta Sánchez
El ecocardiograma. Dra. Violeta Sánchez
 
Manejo de la IC avanzada o refractaria. Dr. Nicolas Manito
Manejo de la IC avanzada o refractaria. Dr. Nicolas ManitoManejo de la IC avanzada o refractaria. Dr. Nicolas Manito
Manejo de la IC avanzada o refractaria. Dr. Nicolas Manito
 
¿Qué aportan las nuevas guías de IC? Dr. Esteban López de Sa
¿Qué aportan las nuevas guías de IC? Dr. Esteban López de Sa¿Qué aportan las nuevas guías de IC? Dr. Esteban López de Sa
¿Qué aportan las nuevas guías de IC? Dr. Esteban López de Sa
 
La responsabilidad del clínico. Dr Juan F. Delgado
La responsabilidad del clínico. Dr Juan F. DelgadoLa responsabilidad del clínico. Dr Juan F. Delgado
La responsabilidad del clínico. Dr Juan F. Delgado
 
Programa ITERA - Dr.Josep Comín
Programa ITERA - Dr.Josep ComínPrograma ITERA - Dr.Josep Comín
Programa ITERA - Dr.Josep Comín
 
Realidad española de los programas de insuficiencia cardiaca. Dr. Josep Lupón
Realidad española de los programas de insuficiencia cardiaca. Dr. Josep LupónRealidad española de los programas de insuficiencia cardiaca. Dr. Josep Lupón
Realidad española de los programas de insuficiencia cardiaca. Dr. Josep Lupón
 

Recently uploaded

Forensic Nursing powerpoint presentation
Forensic Nursing powerpoint presentationForensic Nursing powerpoint presentation
Forensic Nursing powerpoint presentationKavitha Krishnan
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communicationskatiequigley33
 
Understanding AIDS:a roadmap to well ess
Understanding AIDS:a roadmap to well essUnderstanding AIDS:a roadmap to well ess
Understanding AIDS:a roadmap to well essAbhishekKumar524514
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Vaikunthan Rajaratnam
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyMedicoseAcademics
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxNaveenkumar267201
 
Arthroscopic Surgery in Indore : A Minimally Invasive Guide to Joint Health
Arthroscopic Surgery in Indore : A Minimally Invasive Guide to Joint HealthArthroscopic Surgery in Indore : A Minimally Invasive Guide to Joint Health
Arthroscopic Surgery in Indore : A Minimally Invasive Guide to Joint HealthGokuldas Hospital
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationMedicoseAcademics
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxkomalt2001
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.kishan singh tomar
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.whalesdesign
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .Mohamed Rizk Khodair
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.pptRamDBawankar1
 
Cure of patients which terminally ill.pdf
Cure of patients which terminally ill.pdfCure of patients which terminally ill.pdf
Cure of patients which terminally ill.pdfrg0000009
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsMedicoseAcademics
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)kishan singh tomar
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptxNIKITA BHUTE
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024EwoutSteyerberg1
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionkrishnareddy157915
 

Recently uploaded (20)

Forensic Nursing powerpoint presentation
Forensic Nursing powerpoint presentationForensic Nursing powerpoint presentation
Forensic Nursing powerpoint presentation
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communications
 
Understanding AIDS:a roadmap to well ess
Understanding AIDS:a roadmap to well essUnderstanding AIDS:a roadmap to well ess
Understanding AIDS:a roadmap to well ess
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before Pregnancy
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
 
Arthroscopic Surgery in Indore : A Minimally Invasive Guide to Joint Health
Arthroscopic Surgery in Indore : A Minimally Invasive Guide to Joint HealthArthroscopic Surgery in Indore : A Minimally Invasive Guide to Joint Health
Arthroscopic Surgery in Indore : A Minimally Invasive Guide to Joint Health
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptx
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
 
Cure of patients which terminally ill.pdf
Cure of patients which terminally ill.pdfCure of patients which terminally ill.pdf
Cure of patients which terminally ill.pdf
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functions
 
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung function
 

Antagonistas del receptor de la Adenosina A1: nuevo paradigma en el tratamiento de la IC Aguda. Dr. José Luis López Sendón

  • 1. Disclosure Information: clinical research grants from: BMS, Bayer Jose López-Sendón Hospital Universitario La Paz. Madrid Antagonistas del receptor A1 de Adenosina Nuevo pardigma en el tratamiento de la insuficiencia cardiaca aguda
  • 2. The old times. Heart failure as a congestive syndrome
  • 3. Adams KF et al. Am Heart J. 2005; 149: 209 Cleland JGF et al. Eur Heart J. 2003; 24: 442 Fonarow GC et al. J Am Coll Cardiol. 2005; 45: 345A Hospitalizations for HF: Patient Characteristics ADHERE EURO HF OPTIMIZE-HF (%) (107,920 pts.) (11,327 pts.) (48,612 pts.) Any dyspnea 89 70 90? Dyspnea at rest 34 40 45 Fatigue 32 35 23 Rales 68 N/A 65 Peripheral edema 66 23 65
  • 4. 60-Day All-cause Mortality 0% 10% 20% N = 204 115 (64%) (36%) ACTIVE in CHF Adapted from Gheorghiade M et al. JAMA. 2004;291:1963 Congestion after Initial In-Hospital Therapy is Associated with Higher 60-day Mortality Severe Congestion* 7.8 3.5 No Severe Congestion*
  • 5. Bayliss et al. Br Heart J. 1987; 57: 17 Neurohormonal effect of Diuretics in Heart Failure Basal (n=12) Plasma Renin Activity (ng/mL/h) 50 10 2.5 0.5 P =.0002 After Diur étic (n=11) Plasma Aldosterone (pmol/L) % 1000 600 200 100 P =.0007 Basal (n=12) After Diuretic (n=11)
  • 6. Resistencia a diuréticos Incremento de la Mortalidad y Morbilidad Tratamiento diur ético Insuficiencia renal Disminuci ón de la función renal Desarrollo de Resistencia a Diur éticos Disminuci ón Flujo sanguíneo Activaci ón Neurohormonal
  • 7. Incidencia de Insuf. Renal en Insf. Cardiaca 13 10 4 12 9 6 41 21 16 27 1.8 30 0 5 10 15 20 25 30 35 ADHERE OSCUR internista OSCUR cardiologo HGM cardiologo ICCAR ambulatorio EHFS-1 Rusia EHFS 1 Holanda EHFS-1 España EHFS-1 Media EVEREST VALIANT MADIT 2 Registros Ensayos cl ínicos % EHFS-2 ICC EHFS-2 ICA 21 11 0 5 10 15 20 25 30 35
  • 8. Incidencia de IR en IC 43,3% 41,8% Pacientes (nº) FEVI ≥ 50% FEVI < 50% Insuficiencia Renal: TFG < 60 ml/min/1.73m2 Grigorian L, et al . REC 2006:59:99
  • 9. Insuficiencia cardiaca aguda Factores relacionados con Mortalidad intrahospitalaria EHFS-II: n=3432 L ó pez-Send ón et al ECC 2007
  • 10. Función Renal y Pron óstico FEVI ≥ 50% FEVI < 50% Grigorian L, et al . REC 2006:59:99 TFG < 30 TFG < 30 TFG 30-60 TFG 30-60 TFG > 60 TFG > 60 RR (ajustado) TFG<30/>60 : 2.86; p=0.021 RR (ajustado) TFG<30/>60 : 3.79; p=0.011 RR (ajustado) TFG 30-60/>60 : 1.44; p=NS RR (ajustado) TFG 30-60/>60 : 1.02; p=NS
  • 11. NA + and H 2 O RETENTION SNS 1 Efferent art. constriction 2 Na + reabs. in prox. tubule Angiotensin 1 Efferent art. constriction 2 Na + reabs. in prox. tubule Aldosterone 3 Reabsorption H 2 O and Na+ 4 K + Secretion Vasopressin 5 H 2 O reabs. in collecting tubule 6 Na + reabs. in ascending branch of the loop of Henle Adenosin 1b A fferent art. constriction 1 Na + reabs. in prox. tubule Atrial Natriuretic P 7 Increase glomerular filtration 8 Na reabs. in collecting tubule Renal Prostaglandins 9 Afferent art. vasodilatation 10 Reduce Na + reabsorption in asc. branch of loop of Henle 11 Inhibit Na + reabsorption in collecting tubule 12 1 2 4 5 6 7 8 9 10 3 1b
  • 12. New Diuretics ? • BNP • Endotelin antagonists • Adenosin receptor inh. • Vasopresin antagonists • Aldosterone inhibitors
  • 13. Adenosin A1 Receptors Reabsorción de Na+ Vasoconstricción Adenosin A1 receptors: Afferent arteriolar vasodilatation Inhibit Na + reabsorption in the proximal tubule and enhance diuresis Block adenosine-mediated tubo-glomerular feedback .
  • 14.
  • 15. A1 receptor Blockers Rolofillyne (KW-3902) BG9928 BG9719 (CVT-124) SLV320
  • 16. BG9719, an A1R antagonist, protects against the decline in renal function observed with diuretic therapy n = 63, NYHA class II-IV, EF  40% and edema despite furosemide (80 mg/d) IV BG9928 (3, 15, 75 y 225 mg) vs placebo for 10 days BG9719 increased urine output, sodium excretion and GFR Furosemide increased urine output at the expense of decreased GFR BG9719 plus furosemide increased diuresis without deterioration in GFR Decrease in body weight of 0.6 kg (0.3 kg with placebo) Gottlieb et al. JACC 2000;35:56-59
  • 17. CKI-201 - ADHF patients with renal impairment Cumulative Urine Volume and daily dose of i.v. furosemide Day 1 Day 2 Day 3 0 40 80 120 160 * Daily dose of i.v. Furosemide (mg) * P < 0.05 vs. placebo). Givertz et al. JACC 2007; 50:1551-1560 By day 4 or day of discharge if earlier, i.v. furosemide administration tended to be lower in the KW-3902 group Placebo 2.5 mg 30 mg 60 mg 15 mg
  • 18. CKI-202 – ADHF patients refractory to diuretics Hourly Urine Volume and Creatinine Clearance (34 ml/min) * P < 0.05 vs. placebo Givertz et al. JACC 2007; 50:1551-1560 Enhances the response to loop diuretics and may have a renal protective effect I ncrease Na + excretion that with &quot;little kaliuresis“ Decreases BW, improves dyspnea and edemas No change in morbidity and mortality for worsening of HF
  • 19. Pilot study 301 patients Barry M. Massie For the PROTECT Investigators and Coordinators
  • 20.
  • 21.
  • 22. PROTECT Primary Endpoint 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Placebo (n=78) 10 mg (n=74) 20 mg (n=75) 30 mg (n=74) Treatment group % subjects Failure Unchanged Success
  • 23. PROTECT 60 Day Outcomes: Death and Rehospitalization 1 30 mg vs placebo: HR 0.55 (95% CI = 0.28,1.04) Placebo Rolofylline (n=78) 10 mg (n=74) 20 mg (n=75) 30 mg (n=74) Death or cardiovascular or renal rehospitalization 1 33% 32% 24% 19% Death 10% 12% 8% 5% Rehospitalization for cardiovascular or renal causes 30% 22% 17% 16%
  • 24.
  • 25.  
  • 26. Conclusions • Adenosin harmful in HF • A1 blockade promissing in Acute HF • Protect trial a deception • Drug w real benefit in acute heart failure still missing (and much needed)

Editor's Notes

  1. Side effects - GI symptoms and injection site pain at higher doses, which dissipated within minutes after the infusion ended